The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| TCRT | +99% | -99.08% | -60.83% | -99% |
| S&P | +15.37% | +82.64% | +12.79% | +457% |
Alaunos Therapeutics, Inc. is a biopharmaceutical company and clinical-stage oncology-focused cell therapy company, which engages in the development of adoptive TCR engineered T-cell therapies, or TCR-T, designed to treat multiple solid tumor types in large cancer patient populations with unmet clinical needs. Its pipeline includes Library TCR-T cell and mblL-15 TCR-T cell Therapy. The company was founded in 2003 and is headquartered in Houston, TX.
Four of the biotech's top managers reveal they've exercised stock options, and investors are following suit by snapping up shares.
The biotech is rebounding after yesterday's big sell-off.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | $0.00M | 0.0% |
| Gross Margin | 75.00% | 0.0% |
| Market Cap | $5.32M | 3.1% |
| Market Cap / Employee | $5.32M | 0.0% |
| Employees | 1 | 0.0% |
| Net Income | -$1.16M | -2.8% |
| EBITDA | -$1.19M | -3.2% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $1.94M | 15.2% |
| Accounts Receivable | $0.00M | 0.0% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.00M | 0.0% |
| Short Term Debt | $0.00M | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -110.67% | -8.2% |
| Return On Invested Capital | -207.79% | -21.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$0.94M | -20.5% |
| Operating Free Cash Flow | -$0.84M | -8.1% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 1.12 | 1.14 | 7.34 | 1.37 | -0.11% |
| Price to Sales | 338.93 | 235.38 | 1355.05 | 876.85 | 2.04% |
| Price to Tangible Book Value | 1.12 | 1.14 | 7.34 | 1.37 | -0.11% |
| Enterprise Value to EBITDA | -2.59 | -1.86 | -5.05 | -2.80 | -7.30% |
| Return on Equity | -111.8% | -139.1% | -107.5% | -145.6% | 2.76% |
| Total Debt | $0.00M | $0.00M | $0.00M | $0.00M | - |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
